BIO DEGRADABLE POLYMERIC NANOPARTICLE FOR THEAPEUTICE CANCER
Abstract
Biodegradable polymeric nanoparticles have emerged as an advanced and promising platform in cancer therapeutics.These nanoparticles are capable of encapsulating anticancer drugs and delivering them selectively to tumour sites.They help to improve bioavailability, reduce systemic toxicity, and enhance therapeutic index.Polymers such as PLGA, PLA, PCL, and chitosan are commonly used due to their biocompatibility and controlled degradation nature.By modifying particle size and surface properties, nanoparticles achieve enhanced permeability and retention (EPR) effect for passive tumour targeting.Surface functionalization with ligands, antibodies, or peptides further allows active targeting of specific cancer cell receptors.This improves cellular uptake and reduces drug loss during circulation.Biodegradable polymeric nanoparticles also offer sustained and controlled drug release, decreasing frequent dosing requirements. Many anticancer drugs like doxorubicin, paclitaxel, and cisplatin have been successfully loaded in such polymeric systems.Nanoparticle-based therapy can overcome issues of drug resistance and poor solubility of hydrophobic anticancer agents.These carriers also protect drugs from enzymatic degradation before reaching the tumour.Preclinical studies have demonstrated significant tumour growth inhibition and reduced side effects.Advanced nanocarriers can also co-deliver multiple drugs for combination cancer therapy.This helps in synergistic action and improved treatment response.Biodegradable nature ensures safe metabolite formation and minimal residue accumulation in tissues.Overall, polymeric nanoparticles represent a safe, effective, and targeted platform for cancer management.Future research is focused on clinical translation, scalability, and regulatory acceptance.Personalized nanomedicine and precision drug delivery can be achieved through these systems.Therefore, biodegradable polymeric nanoparticles hold great potential for next-generation therapeutic cancer treatment.They are a transformative approach in modern oncology and nanotechnology-based drug delivery.
Downloads
References
M. Daniyal, B. Liu, W. Wang, Comprehensive review on graphene oxide for use in drug delivery system, Curr. Med. Chem. 27 (22) (Jun. 2020) 3665–368
S. Prakash, Nano-based drug delivery system for therapeutics: a comprehensive review, Biomed. Phys. Eng. Express 9 (5) (Aug. 2023) 052002
K.. Djayanti et al., “Mesoporous silica nanoparticles as a potential nanoplatform: therapeutic applications and considerations,” Int. J. Mol. Sci. 2023, Vol. 24, Page 6349, vol. 24, no. 7, p. 6349,Mar.2023.do
U.. Hani, et al., Recent advances in novel drug delivery systems for management of breast cancer: a comprehensive review, J. Drug Deliv. Sci. Technol. 56 (Apr. 2022)
X. Cheng, Q. Xie, Y. Sun, Advances in nanomaterial-based targeted drug delivery systems, Front. Bioeng. Biotechnol. 11 (Apr. 2023) 1177151
H. Shabbir, E. Csapo, ´ and M. Wojnicki, “Carbon quantum dots: the role of surface functional groups and proposed mechanisms for metal ion sensing,” Inorganics 2023, Vol. 11, Page 262, vol. 11, no. 6, p. 262, Jun2023
S. Nsairat, D. Khater, U. Sayed, F. Odeh, A. Al Bawab, W. Alshaer, Liposomes: structure, composition, types, and clinical applications, Heliyon 8 (5) (May 2022)
Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, et al. 2014 Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. USA 111: 11449–54
Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, et al. 2016 Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced tumors. Clin. Cancer Res 22: 3157–63
Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, et al. 2011 A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104: 593–8
Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, et al. 2013 First-inhuman phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 31: 986-1000
Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, et al. 2015 Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin. Cancer Res 21: 808–18
Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, et al. 2007 A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer 97: 170–76 [PubMed: 17595665]
Kato K, Chin K, Yoshikawa T, Yamaguchi K, Tsuji Y, et al. 2012 Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30:16
Kreuter J. Nanoparticles-a historical perspective. Int J Pharm. 2007;331:1–10
Li R, Wu R, Zhao L, Wu M, Yang L, Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano. 2010;4:1399–408
Lyra KM, Kaminari A, Panagiotaki KN, Spyrou K, Papageorgiou S, Sakellis E, et al. Multi-walled carbon nanotubes decorated with guanidinylated dendritic molecular transporters: an efcient platform for the selective anticancer activity ofdoxorubicin.Pharmaceutics.2021.https://doi.org/10.3390/pharmaceutics13060858
Kim SW, Kyung Lee Y, Yeon Lee J, Hee Hong J, Khang D. PEGylated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells. Nanotechnology. 2017.
Li L, Gu W, Chen J, Chen W, Xu ZP. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials.
Senapati S, Thakur R, Verma SP, Duggal S, Mishra DP, Das P, et al. Layered double hydroxides as efective carrier for anticancer drugs and tailoring of release rate through interlayer anions. J Control Release.
Maier-Hauf K, Ulrich F, Nestler D, Niehof H, Wust P, Thiesen B, et al. Efcacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103:317–24
Hiremath CG, Heggnnavar GB, Kariduraganavar MY, Hiremath MB. Codelivery of paclitaxel and curcumin to foliate positive cancer cells using Pluronic-coated iron oxide nanoparticles. Prog Biomater. 2019;8:155–6
Javid A, Ahmadian S, Saboury AA, Kalantar SM, Rezaei-Zarchi S. Chitosan-coated superparamagnetic iron oxide nanoparticles for doxorubicin delivery: synthesis and anticancer efect against human ovarian cancer cells. Chem Biol Drug Des. 2013;82:296–306.
Liu J, Bu W, Pan L, Shi J. NIR-triggered anticancer drug delivery by upconverting nanoparticles with integrated azobenzene-modifedmesoporous silica. Angew Chemie. 2013;125:4471–5
Chen Z, Li Z, Lin Y, Yin M, Ren J, Qu X. Bioresponsive hyaluronic acidcapped mesoporous silica nanoparticles for targeted drug delivery. Chem A Eur J. 2013;19:1778–83.
Iannazzo D, Pistone A, Celesti C, Triolo C, Patané S, Giofré SV, et al. A smart nanovector for cancer targeted drug delivery based on graphene quantum dots. Nanomaterials. 2019;9:1–17
Campbell E, Hasan MT, Gonzalez-Rodriguez R, Truly T, Lee BH, Green KN, et al. Graphene quantum dot formulation for cancer imaging and redox-based drug delivery. Nanomed Nanotechnol Biol Med. 2021.
Shang Y, Wang Q, Wu B, Zhao Q, Li J, Huang X, et al. Platelet-membranecamoufaged black phosphorus quantum dots enhance anticancer efect mediated by apoptosis and autophagy. ACS Appl Mater Interfaces. 2019;11:28254–66.
Fatimah I, Fadillah G, Yudha SP. Synthesis of iron-based magnetic nanocomposites: a review. Arab J Chem. 2021;14:103301
Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles.
Mahatol R.Nanoemulsion as targeted drug delivery system for cancer therapeutics.J Pharma Sci Pharmacol.2017;3.83-97
Narayanaswamy R,Torchillin VP.Hydrogels and their application in targeted drug delivery.Molecules.2019
Chen H, Liu T, Su Z, Shang L, Wei G. 2D transition metal dichalcogenide nanosheets for photo/thermo-based tumor imaging and therapy. Nanoscale Horizons. 2018;3:74–89.
Tang X, Du A, Kou L. Gas sensing and capturing based on two-dimensional layered materials: overview from theoretical perspective. WIREs Comput Mol Sci. 2018.
Xing C, Chen S, Qiu M, Liang X, Liu Q, Zou Q, et al. Conceptually novel black phosphorus/cellulose hydrogels as promising photothermal agents for efective cancer therapy. Adv Healthc Mater. 2018;7:1701510.
Liu Z, Chen H, Jia Y, Zhang W, Zhao H, Fan W, et al. A two-dimensional fngerprint nanoprobe based on black phosphorus for bio-SERS analysis and chemo-photothermal therapy. Nanoscale. 2018;10:18795–80
Peng L, Mei X, He J, Xu J, Zhang W, Liang R, et al. Monolayer nanosheets with an extremely high drug loading toward controlled delivery and cancer theranostics. Adv Mater. 2018;30:1707389.
Yu J, Lin Y-H, Yang L, Huang C-C, Chen L, Wang W-C, et al. Improved anticancer photothermal therapy using the bystander efect enhanced by antiarrhythmic peptide conjugated dopamine-modifed reduced graphene oxide nanocomposite. Adv Healthc Mater. 2017;6:1600804.
Xing C, Chen S, Qiu M, Liang X, Liu Q, Zou Q, et al. Conceptually novel black phosphorus/cellulose hydrogels as promising photothermal agents for efective cancer therapy. Adv Healthc Mate
J. Estelrich, M.J. Sanchez-Martín, ´ M.A. Busquets, Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents, Int. J. Nanomedicine 10 (Mar. 2015) 1727,
S.M. Hosseini, J. Mohammadnejad, S. Salamat, Z. Beiram Zadeh, M. Tanhaei, S. Ramakrishna, Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review, Mater Today Chem. 29 (Apr. 2023)
J. Estelrich, M.J. Sanchez-Martín, ´ M.A. Busquets, Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents, Int. J. Nanomedicine 10(Mar. 2015) 1727,
P. Zhang, Y. Li, W. Tang, J. Zhao, L. Jing, K.J. McHugh, Theranostic nanoparticles with disease-specific administration strategies, Nano Today 42 (Feb. 2022) 101335,
25. Dang JM, Leong KW. 2006 Natural polymers for gene delivery and tissue engineering. Advanced Drug Delivery Reviews 58: 487–99 [PubMed: 16762443]
Abadjian, M. Z., Edwards, W. B., and Anderson, C. J. (2017). Imaging the tumormicroenvironment. Adv. Exp. Med. Biol. 1036, 229–257. doi:10.1007/978-3-319-67577-0_15
Abu Lila, A. S., Kiwada, H., and Ishida, T. (2013). The accelerated blood clearance(ABC) phenomenon: clinical challenge and approaches to manage. J. Contr.Release 172, 38–47. doi:10.1016/j.jconrel.2013.07.026
Abuchowsky, A., van Es, T., Palczuk, N. C., and Davis, F. F. (1977). Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578–3581.
Adrianzen Herrera, D., Ashai, N., Perez-Soler, R., and Cheng, H. (2019). Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expet Opin. Pharmacother. 20, 95–102. doi:10.1080/14656566.2018.1546290
Akash, M. S. H., and Rehman, K. (2015). Recent progress in biomedical applications of pluronic (PF127): pharmaceutical perspectives. J. Contr.Release 209, 120–138. doi:10.1016/j.jconrel.2015.04.032
Alberg, I., Kramer, S., Schinnerer, M., Hu, Q., Seidl, C., Leps, C., et al. (2020).Polymeric nanoparticles with neglectable protein corona. Small 16, 1907574.doi:10.1002/smll.201907574
Alcázar-Alay, S. C., and Meireles, M. A. A. (2015). Physicochemical properties,modifications and applications of starches from different botanical sources.Food Sci. Technol. 35, 215–236. doi:10.1590/1678-457X.6749
Cai, H., Dai, X., Wang, X., Tan, P., Gu, L., Luo, Q., et al. (2020). A nanostrategy for efficient imaging-guided antitumor therapy through a stimuli-responsive branched polymeric prodrug. Adv. Sci. 7, 1903243. doi:10.1002/advs.201903243
Cai, R., and Chen, C. (2019). The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater. 31, 1805740. doi:10.1002/adma.201805740
Caputo, F., Clogston, J., Calzolai, L., Rösslein, M., and Prina-Mello, A. (2019).Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J. Contr.Release 299, 31–43. doi:10.1016/j.jconrel.2019.02.030
Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., et al.(2007). Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc.Natl. Acad. Sci. U. S. A. 104, 2050–2055. doi:10.1073/pnas.0608582104
Copyright (c) 2025 IJRDO - JOURNAL OF BIOLOGICAL SCIENCE
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
